Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy - A report of long-term follow-up of serial cases and literature review

Clinical Rheumatology

Volumn 33, Issue 4, 2014, Pages 577-586

  Xuan, Dandan ^a   Yu, Yiqi ^a   Shao, Linyun ^a   Wang, Jiali ^a   Zhang, Wenhong ^a,b   Zou, Hejian ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Disease modifying anti rheumatic drugs; Hepatitis B; Rheumatic disease; Steroid; Tumor necrosis factor alpha blocking agent

Indexed keywords

ADEFOVIR; AMINOTRANSFERASE; ANTIRHEUMATIC AGENT; AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNA; ENTANERCEPT; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; BRAIN INFARCTION; CLINICAL ARTICLE; DERMATOMYOSITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; FOLLOW UP; HEPATITIS; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER FUNCTION; LONG TERM CARE; MIDDLE AGED; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; TREATMENT OUTCOME; VIRUS REACTIVATION; YOUNG ADULT; ARTHRITIS, RHEUMATOID; COHORT ANALYSIS; COMPLICATION; FEMALE; HEPATITIS B, CHRONIC; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PHYSIOLOGY; RHEUMATIC DISEASES; SPONDYLITIS, ANKYLOSING; VIRUS ACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; ARTHRITIS, RHEUMATOID; AZATHIOPRINE; COHORT STUDIES; DERMATOMYOSITIS; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDNISONE; RHEUMATIC DISEASES; SPONDYLITIS, ANKYLOSING; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84898902699     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2450-9     Document Type: Review

References (45)

1. Lee WM (1997) Hepatitis B virus infection. N Engl J Med 337(24):1733-1745. doi: 10.1056/NEJM199712113372406
2. Perrillo RP (2001) Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120(4):1009-1022
3. EASL clinical practice guidelines (2012) Management of chronic hepatitis B virus infection. J Hepatol 57(1):167-185. doi: 10.1016/j.jhep.2012.02.010
4. Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B virus infection. J Hepatol 46(1):160-170. doi: 10.1016/j.jhep.2006.10.007
5. Zanati SA, Locarnini SA, Dowling JP, Angus PW, Dudley FJ, Roberts SK (2004) Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine. J Clin Virol 31(1):53-57. doi: 10.1016/j.jcv.2004.02.013
6. Yang CH, Wu TS, Chiu CT (2007) Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 157(3):587-590. doi: 10.1111/j.1365-2133.2007.08058.x
7. Wendling D, Di Martino V, Prati C, Toussirot E, Herbein G (2009) Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Jt Bone Spine 76(3):308-311. doi: 10.1016/j.jbspin.2008.11.005
8. Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S, Toussirot E, Miguet JP, Herbein G, Di Martino V (2005) Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64(5):788-789. doi: 10.1136/ard.2004.031187
9. Watanabe K, Takase K, Ohno S, Ideguchi H, Nozaki A, Ishigatsubo Y (2012) Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Mod Rheumatol 22(3):470-473. doi: 10.1007/s10165-011-0521-9
10. Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H (2010) Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol 22(4):494-499
11. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AI (2010) Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 69(7):1352-1355. doi: 10.1136/ard.2009.127233
12. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, Motomura S (2011) Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 21(1):16-23. doi: 10.1007/s10165-010-0337-z
13. Tan J, Zhou J, Zhao P, Wei J (2012) Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 31(8):1169-1175. doi: 10.1007/s10067-012-1988-2
14. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N (2011) Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 46(4):556-564. doi: 10.1007/s00535-010-0367-5
15. Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, Park MC, Park YB, Bae SC, Yoo WH, Kim SI, Lee EB, Song YW (2012) Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFalpha agents: a retrospective analysis of 49 cases. Clin Rheumatol 31(6):931-936. doi: 10.1007/s10067-012-1960-1
16. Rodriguez-Escalera C, Fernandez-Nebro A (2008) The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology (Oxford) 47(11):1732-1733. doi: 10.1093/rheumatology/ken362
17. Robinson H, Walker-Bone K (2009) Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford) 48(4):448-450. doi: 10.1093/rheumatology/kep003
18. Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S (2011) Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 31(3):403-404. doi: 10.1007/s00296-009-1202-2
19. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S (2003) Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62(7):686-687
20. Oshima Y, Tsukamoto H, Tojo A (2012) Association of hepatitis B with antirheumatic drugs: a case-control study. Mod Rheumatol. doi: 10.1007/s10165-012-0709-7
21. Nakanishi K, Ishikawa M, Nakauchi M, Sakurai A, Doi K, Taniguchi Y (1998) Antibody to hepatitis B e positive hepatitis induced by withdrawal of steroid therapy for polymyositis: response to interferon-alpha and cyclosporin A. Intern Med 37(6):519-522
22. Mori S (2011) Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol 21(6):621-627. doi: 10.1007/s10165-011-0458-z
23. Matsumoto T, Marusawa H, Dogaki M, Suginoshita Y, Inokuma T (2010) Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection. Liver Int 30(8):1241-1242. doi: 10.1111/j.1478-3231.2010.02238.x
24. Li X, Tian J, Wu J, He Q, Li H, Han F, Li Q, Chen Y, Ni Q, Chen J (2009) A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study. Clin Ther 31(4):741-750. doi: 10.1016/j.clinthera. 2009.04.011
25. Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS (2011) Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 70(10):1719-1725. doi: 10.1136/ard.2010.148783
26. Kishida D, Okuda Y, Onishi M, Takebayashi M, Matoba K, Jouyama K, Yamada A, Sawada N, Mokuda S, Takasugi K (2011) Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol 21(2):215-218. doi: 10.1007/s10165-010-0365-8
27. Kaur PP, Chan VC, Berney SN (2008) Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol 27(8):1069-1071. doi: 10.1007/s10067-008-0896-y
28. Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, Kikuchi M, Yoshida K, Nakano M, Gejyo F (2001) Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 44(2):339-342. doi: 10.1002/1529-0131(200102)44:2<339::AID-ANR51>3.0.CO;2-Q
29. Germanidis G, Hytiroglou P, Zakalka M, Settas L (2012) Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol 56(6):1420-1421. doi: 10.1016/j.jhep.2011. 10.011
30. Durmus O, Tekin L, Carli AB, Cakar E, Acar A, Ulcay A, Dincer U, Kiralp MZ (2013) Hepatitis B virus reactivation in a juvenile rheumatoid arthritis patient under treatment and its successful management: a complicated case. Rheumatol Int 33(5):1345-1349. doi: 10.1007/s00296-011-2244-9
31. Doubrawa E, Ricca RA, Malucelli TO, Pizzol VI, Barros DH, Paiva ES (2012) Use of infliximab in a patient with rheumatoid arthritis and chronic hepatitis B. Rev Bras Reumatol 52(4):653-655
32. Chung SJ, Kim JK, Park MC, Park YB, Lee SK (2009) Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 36(11):2416-2420. doi: 10.3899/jrheum.081324
33. Cho YT, Chen CH, Chiu HY, Tsai TF (2012) Use of anti-tumor necrosis factor-alpha therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol 39(3):269-273. doi: 10.1111/j.1346-8138.2011.01434.x
34. Cheng J, Li JB, Sun QL, Li X (2011) Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases. J Rheumatol 38(1):181-182. doi: 10.3899/jrheum.100692
35. Charpin C, Guis S, Colson P, Borentain P, Mattei JP, Alcaraz P, Balandraud N, Thomachot B, Roudier J, Gerolami R (2009) Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 11(6):R179. doi: 10.1186/ar2868
36. Carroll MB, Bond MI (2008) Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 38(3):208-217. doi: 10.1016/j.semarthrit.2007.10.011
37. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P (2010) Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken) 62(6):749-754. doi: 10.1002/acr.20130
38. Cansu DU, Kalifoglu T, Korkmaz C (2008) Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 35(3):421-424
39. Bae JH, Sohn JH, Lee HS, Park HS, Hyun YS, Kim TY, Eun CS, Jeon YC, Han DS (2012) A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier. Clin Mol Hepatol 18(2):225-228. doi: 10.3350/cmh.2012.18.2.225
40. Anelli MG, Torres DD, Manno C, Scioscia C, Iannone F, Covelli M, Schena FP, Lapadula G (2005) Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 52(8):2519-2520. doi: 10.1002/art.21216
41. Andres M, Courtney P (2011) No hepatitis B reactivation in a patient with refractory antisynthetase syndrome successfully treated with rituximab. Jt Bone Spine 78(6):653-654. doi: 10.1016/j.jbspin.2011.05.017
42. Ghrenassia E, Mekinian A, Rouaghe S, Ganne N, Fain O (2012) Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Jt Bone Spine 79(1):100-101. doi: 10.1016/j.jbspin.2011.07.003
43. Nordgaard-Lassen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, Ravn P, Sorensen IJ, Theede K, Tjellesen L (2012) Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J 59(7):C4480
44. Gwak GY, Koh KC, Kim HY (2007) Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol 25(6):888-889
45. Wu JM, Huang YH, Lee PC, Lin HC, Lee SD (2009) Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma. J Clin Gastroenterol 43(5):496-498. doi: 10.1097/MCG.0b013e3181945942